GlassScriptPhysician profile
Asra S Husain
NPI 1275795387
$34,103.18
in general payments reported to CMS, 2019-2025
48 companies · $4,795 in 2025
The $4,795 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,886 · 2020: $1,642 · 2021: $2,380 · 2022: $3,444 · 2023: $8,429 · 2024: $12K · 2025: $4,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $7,965 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,675.00 |
| Food and Beverage | $7,964.87 |
| Education | $111.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18,931.93 | 2021-2025 | |
| Sk Life Science, INC. | $1,559.91 | 2020-2025 | |
| Ucb, INC. | $1,356.44 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Biogen, INC. | $1,261.57 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Eisai INC. | $1,190.86 | 2019-2025 | |
| Genentech USA, INC. | $909.26 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Lilly USA, LLC | $652.80 | 2020-2024 | Kisunla, Emgality, Amyvid |
| Novartis Pharmaceuticals Corporation | $617.06 | 2019-2024 | |
| Emd Serono, INC. | $588.45 | 2019-2025 | Mavenclad |
| Neurelis, INC. | $575.81 | 2020-2024 | Valtoco |
| Allergan, INC. | $452.78 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $433.57 | 2019-2022 | |
| Tg Therapeutics, INC. | $432.39 | 2023-2025 | |
| Acorda Therapeutics, INC | $366.44 | 2021-2024 | Inbrija |
| Alexion Pharmaceuticals, INC. | $350.10 | 2019-2025 | Ultomiris |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asra Husain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.